At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
GX-188E +1 moredrug
Likely dose
GX-188E 1.0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer
In Brief
A Phase 2 clinical trial evaluating GX-188E and KEYTRUDA® for Cervical Cancer. Completed, enrolled 65 participants across 9 sites.
Detailed Summary
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients with Advanced, Non-Resectable HPV-Positive Cervical Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesSouth Korea
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartJun 2018
Primary CompletionApr 2022
Study CompletionDec 2023
TodayJul 2026
First PostedFeb 23, 2018
Enrollment StartJun 19, 2018
Primary CompletionApr 29, 2022
Study CompletionDec 21, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 8.4 years ago
Interventions
GX-188Edrug
GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
KEYTRUDA®drug
pembrolizumab(100mg/4mL/vial), Intravenous administration